Spero's New SP001 Global License
Spero Therapeutics Secures Global License for SP001 from Innovent in Landmark $1.1 Billion Deal
Anonymous
Key Points
1
SP001 is a third-generation Fc-silent anti-CD40L antibody, a design intended to reduce Fc receptor engagement and potentially improve safety in immune-mediated diseases.
2
Spero CEO Esther Rajavelu described the deal as 'the foundation of our new pipeline' and emphasized that the CD40L pathway has broad applicability across multiple autoimmune and inflammatory conditions.
3
In Innovent's broader collaboration history, Takeda's 2025 deal included up to $1.2 billion in upfront payments for IBI363 and IBI343, highlighting the value of Innovent’s early-stage assets.
4
Healthcare Royalty is providing about $105 million in financing to Spero to support its pipeline expansion alongside the SP001 deal.
5
Innovent’s broader pipeline context shows 15 molecules in early clinical development, four in Phase 3 or pivotal trials, two NDAs under regulatory review, and 16 products launched, illustrating the strategic value of global partnerships for accelerating development.
Innovent Biologics and Spero Therapeutics have struck a major drug licensing deal, giving Spero exclusive global rights — outside Greater China — to SP001, a next-generation antibody targeting autoimmune diseases, according to Nasdaq. The deal could pay Innovent up to $1.1 billion in milestone payments, plus tiered royalties on future sales.
SP001, formerly called IBI355, is a third-generation Fc-silent anti-CD40L antibody. In plain terms, it's designed to block a key immune pathway while reducing certain side effects linked to older drugs in the same class. Spero CEO Esther Rajavelu called the deal "the foundation of our new pipeline."
What Spero Gets and What Innovent Keeps
Under the deal, Spero gains rights to develop, make, and sell SP001 everywhere except Greater China, Market Screener reported. Innovent keeps full control of the drug inside Greater China. Spero will pay upfront fees plus potential development, regulatory, and commercial milestones that could reach about $1.1 billion in total.
Innovent also earns tiered royalties on Spero's net sales outside Greater China. Both companies plan separate Phase 2 clinical trials. Spero targets a Phase 2 start for SP001 in IgG4-related disease — a rare inflammatory condition — in Q2 2027. Innovent aims to begin a Phase 2 trial in China for Sjögren's disease by early 2027.
Why the CD40L Target Has Drug Makers Excited
CD40L is a protein that plays a central role in the immune system's inflammatory response. Blocking it can help treat a wide range of autoimmune and inflammatory diseases. Spero's CEO said the CD40L pathway has "broad applicability" across multiple conditions, signaling the company sees SP001 as more than a single-disease drug.
The "Fc-silent" design of SP001 is a key selling point. Older anti-CD40L antibodies caused blood clotting problems because they activated certain immune receptors. SP001's design reduces that receptor engagement, which could make it safer. That safety profile is a major reason Spero is betting heavily on this asset, according to Guru Focus.
$105 Million in Financing Backs Spero's Expansion Plans
To fund its side of the deal and broader pipeline work, Spero secured $105 million in financing from HealthCare Royalty, a firm majority-owned by KKR & Co., according to Yahoo Finance. The funding is non-recourse and non-dilutive, meaning Spero does not give up equity or take on traditional debt obligations tied to its assets.
In exchange, HealthCare Royalty receives a share of future royalties Spero earns. Guru Focus reported the arrangement is structured to preserve Spero's financial flexibility as it moves SP001 through clinical trials. For a clinical-stage biotech, securing this kind of funding without diluting shareholders is considered a significant win.
Innovent's Track Record of Billion-Dollar Global Deals
This deal fits a clear pattern for Innovent. In 2025, Takeda struck a deal with Innovent for two other drugs — IBI363 and IBI343 — with up to $1.2 billion in upfront payments alone, according to Nasdaq. Pfizer has also previously partnered with Innovent, underlining the company's reputation for producing high-value early-stage assets.
Innovent currently has 15 molecules in early clinical development, four in Phase 3 or pivotal trials, and two drugs under regulatory review. It has already launched 16 products. The SP001 deal gives Innovent capital and a global partner to accelerate development while it focuses on the large and growing Chinese market.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
22
Reach
35
A
AnonymousAuthor